[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertriglyceridemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertriglyceridemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,41,64,87,121,156,178,212,243,270,291,313,337,365,390,411,433],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641263","phase-2-a-study-to-assess-the-safety-tolerability-and-efficacy-of-ion775-100641263",false,"NCT07604974","A Study to Assess the Safety, Tolerability and Efficacy of ION775","A Phase 2, Open-label Trial Evaluating the Safety, Tolerability and Efficacy of ION775 in Adults With Hypertriglyceridemia","Key Inclusion Criteria:\n\n1. Adult males and females with HTG (fasting TG more than or equal to (≥) 350 milligrams per deciliter (mg\u002FdL) \\[3.95 millimoles per liter (mmol\u002FL)\\] or with sHTG (fasting TG ≥ 500 mg\u002FdL \\[5.65 mmol\u002FL\\]).\n2. Participants should be on standard of care lipid-lowering medications per local guidelines.\n\nKey Exclusion Criteria:\n\n1. Hemoglobin A1c (HbA1c) ≥ 8.5% at Screening.\n2. Alanine aminotransferase or aspartate aminotransferase \\> 2.0 × upper limit of normal.\n3. Total bilirubin \\> 1.5 upper limit of normal unless due to Gilbert's syndrome.\n4. Estimated GFR \\\u003C 30 mL\u002Fmin\u002F1.73 m\\^2.\n\nNote: Other protocol pre-specified inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},72,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The main objective of this study is to evaluate the effect of ION775 on fasting triglyceride (TG) levels in participants with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG).",[26,27],"Hypertriglyceridemia","Severe Hypertriglyceridemia","RECRUITING","2026-06-17",{"date":31,"type":32},"2026-06-18","ACTUAL",{"date":34,"type":32},"2026-05-12",{"date":36,"type":20},"2028-03",{"name":38,"class":39},"Ionis Pharmaceuticals, Inc.","INDUSTRY",16,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":63},"100619822","phase-3-a-study-of-shr-1918-in-participants-with-hypertriglyceridemia-100619822","NCT07349615","A Study of SHR-1918 In Participants With Hypertriglyceridemia","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypertriglyceridemia","Inclusion Criteria:\n\n1. Male and female ≥ 18 years old, who is able and willing to provide a written informed consent.\n2. 1.7 ≤ TG ≤ 5.6 mmol\u002FL.\n3. LDL-C \\\u003C 3.4 mmol\u002FL.\n4. Male and female subjects of childbearing potential and their partners must have no plans to donate sperm or become pregnant during the entire study period and after the last dose, and agree to use contraceptive methods as specified in the protocol.\n\nExclusion Criteria:\n\n1. History of severe allergies\u002Fhypersensitivity reactions, or clinically significant allergies\u002Fhypersensitivity reactions as judged by the investigator, or history of allergies to drugs with similar chemical structures.\n2. Received or are currently receiving treatment with monoclonal antibodies, siRNA-based drugs, or ASO-based drugs targeting the same target prior to screening.\n3. Have a history of pancreatitis prior to screening or randomization.\n4. Acute ischemic ASCVD events within 3 months prior to screening or randomization.\n5. Heart failure with New York Heart Association (NYHA) Class III-IV prior to screening or randomization.\n6. Malignant tumors within 5 years.\n7. Received plasma exchange therapy within 2 months prior to screening, or plans to receive plasma exchange therapy during the study period, or has received LDL receptor gene therapy prior to screening.\n8. Have a history of diseases that significantly affect blood lipid levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, or have severe arrhythmia prior to screening or randomization.\n9. Poorly controlled type 2 diabetes mellitus or previously diagnosed type 1 diabetes mellitus; poorly controlled hypertension.\n10. Have a history of major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period.",{"count":49,"type":20},360,[51],"PHASE3","The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.",[26],"2026-06-15",{"date":56,"type":32},"2026-06-16",{"date":58,"type":32},"2026-04-01",{"date":60,"type":20},"2027-11",{"name":62,"class":39},"Beijing Suncadia Pharmaceuticals Co., Ltd",1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100579322","phase-3-long-term-safety-and-efficacy-of-plozasiran-in-adults-with-hypertriglyceridemia-100579322","NCT06822790","Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia","A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)","SHASTA-10","Inclusion Criteria:\n\n* Adult males, or nonpregnant (who do not plan to become pregnant), nonlactating adult females, who are able and willing to provide written informed consent prior to the performance of any study-specific procedures\n* Completed all required study visits per protocol in the parent study\n* Female subjects of childbearing potential must agree to use a highly effective method of contraception during the study and for at least 90 days after the End of Study (EOS) or the last dose of plozasiran, whichever is later. Male subjects must agree to use a condom during the study and for at least 90 days after the EOS or last dose of plozasiran whichever is later. Subjects must not donate sperm or eggs during the study and for at least 90 days after the EOS or last dose of plozasiran, whichever is later. Female subjects of childbearing potential on hormonal contraceptives must be stable on medication for \\>1 menstrual cycle prior to Day 1.\n* Subjects must be on standard of care lipid and TG-lowering medications per local guidelines (unless documented as intolerant as determined by the Investigator, including an inability to safely administer or re-administer a specific drug because of fear, preference, genetic, clinical, or metabolic considerations, or due to a previous adverse reaction associated with, attributed to, or caused by specific drug)\n* If the subject has a medical history of clinical atherosclerotic cardiovascular disease (ASCVD) or elevated 10-year ASCVD risk (eg, ≥7.5% per American Heart Association\u002FAmerican College of Cardiology \\[AHA\u002FACC\\] risk calculator for subjects ≥40 years of age or Framingham risk score calculator for subjects under the age of 40), the subject must be on appropriate lipid-lowering therapy as per local standard of care (ie, including moderate-to-high intensity statin, as indicated).\n\nIf the subject has diabetes:\n\n1. Subject must be on optimized antidiabetic regimen as defined by the local standards, Investigator, and institutional practices\n2. Subject must have no events of diabetic ketoacidosis, diabetic decompensation\u002F hyperosmolar hyperglycemic nonketotic coma, diabetes complications, recurrent infections, or hospitalization related to poor glycemic control within 24 weeks of the Day 1 visit - Willing to follow diet counseling and maintain a stable low-fat diet\n\nSubjects in the USA and Canada who completed protocol AROAPOC3-2003 meeting all eligibility criteria (with the exception of inclusion criteria #9 which is not applicable to these subjects) who also meet the following additional criteria may enroll in this trial:\n\n* HbA1c ≤10% within 30 days prior to Day 1\n* Completed AROAPOC3-2001 prior to entry into AROAPOC3-2003 AND either (c) or (d) below:\n* Baseline fasting TG level of ≥500 mg\u002FdL and prior history of acute pancreatitis at the time of enrollment into AROAPOC3-2001\n* Baseline fasting TG level of ≥1000 mg\u002FdL at the time of enrollment into AROAPOC3-2001\n\n  * Subjects who previously met all eligibility requirements for AROAPOC3-3003, or AROAPOC3-3004 and were not permitted to proceed to randomization per Sponsor's direction in order to prevent excessive over-enrollment may also be enrolled in this trial. These subjects must meet all eligibility criteria prior to enrollment (with the exception of inclusion criteria #2 and #8 which are not applicable to these subjects) and have an HbA1c ≤10% within 30 days of Day 1.\n\nExclusion Criteria:\n\n* Subject was permanently discontinued from receiving plozasiran in the parent study due to elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or due to HbA1c elevation that did not respond to antidiabetic regimen\n* Subject withdrew consent for continued study treatment in the parent study\n* Known hypersensitivity to the active substance or to any of the excipients of plozasiran\n* Known hypersensitivity to the active substance or to any of the excipients of plozasiran\n* Any new condition or worsening of existing condition or any other situation that in the Investigator's judgment, would make the subject unsuitable for enrollment, could interfere with the subject participating in or completing the study, would make it difficult to comply with protocol requirements, or put the subject at an additional safety risk\n* Unwilling to limit alcohol consumption to within moderate limits for the duration of the study.\n* Poorly controlled glycemia (ie, HbA1c \\>10%) based upon the most recent HbA1c level reported in the parent trial prior to Day 1\n* Acute pancreatitis within 4 weeks prior to Day 1\n* Use of any hepatocyte-targeted siRNA that targets lipids and\u002For triglycerides within 365 days before Day 1 (except plozasiran or inclisiran, which are permitted). Administration of inclisiran must be separated from administration of plozasiran by at least 4 weeks throughout the treatment period\n* Use of any other hepatocyte targeted siRNA or antisense oligonucleotide molecule within 60 days or within 5 half-lives before Day 1 based on plasma PK, whichever is longer.\n* Use of an investigational agent (other than plozasiran) or device within 30 days or within 5 half-lives, based on plasma PK, whichever is longer, prior to Day 1 (V1) or current participation in an interventional investigational study.\n* Recent unstable or symptomatic cardiac arrhythmia (including any associated medication changes) within 90 days prior to Day 1. Individuals with stable well-controlled atrial arrhythmias will be allowed to participate in the study.\n* Uncontrolled hypertension (ie, seated systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg) at Day 1; subject may be re-evaluated when hypertension is controlled.\n\nNote: Other inclusion\u002Fexclusion criteria may apply per protocol",{"count":73,"type":20},869,[51],"This is an open-label study to be conducted in adults with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (SHTG). Each participant must have completed all required visits per protocol in the parent study AROAPOC3-2003 (USA and Canada participants only; NCT# 05413135), AROAPOC3-3001(Canada and Japan participants only; NCT05089084), AROAPOC3-3003 (NCT06347003), AROAPOC3-3004 (NCT06347016) or AROAPOC3-3009 (Argentina, Italy, South Africa, and Spain; NCT06347133).\n\nSubjects who previously met all eligibility requirements for AROAPOC3-3003 or AROAPOC3-3004 and were not permitted to proceed to randomization per the Sponsor's direction in order to prevent excessive over-enrollment may also be enrolled in this trial. The subjects must meet all other applicable eligibility criteria prior to enrollment and have an HbA1c results of \\\u003C=10% within 30 days prior to Day 1.\n\nSubjects entering this OLE from AROAPOC3-2003 must meet the following additional criteria to be considered for enrollment in addition to applicable eligibility criteria:\n\n1. HbA1c ≤10% within 30 days prior to Day 1\n2. Completed AROAPOC3-2001 prior to entry into AROAPOC3-2003 AND fulfill either (c) or (d)\n3. Baseline fasting TG level of ≥500 mg\u002FdL and prior history of acute pancreatitis at the time of enrollment into AROAPOC3-2001\n4. Baseline fasting TG level of ≥1000 mg\u002FdL at the time of enrollment into AROAPOC3-2001\n\nAll eligible participants will receive plozasiran administered subcutaneously (SC) approximately every 3 months for 24 months. Participants will be counseled to remain on the specified low-fat diet throughout the study in accordance with local standard of care.",[26],"2026-05-30",{"date":79,"type":32},"2026-06-02",{"date":81,"type":32},"2025-04-09",{"date":83,"type":20},"2028-07",{"name":85,"class":39},"Arrowhead Pharmaceuticals",275,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":63},"100639253","phase-4-glp-1-agonists-for-prevention-of-recurrent-hypertriglyceridemic-acute-pancreatitis-100639253","NCT07617155","GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis","Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence: Protocol for a Randomized Clinical Trial","RECAP-GLP1","Inclusion Criteria\n\n* Age ≥ 18 years old\n* Previous diagnosis of index HTG-AP (defined as AP with serum TG \\>1000 mg\u002FdL or a serum TG level of 500-1000 mg\u002FdL accompanied by chylous serum)36-38\n* Having HTG as the exclusive cause of AP\n* Time from discharge of index HTG-AP to recruitment between 4 weeks to 3 months, without AP-related symptoms between discharge and recruitment\n* Expression of the willingness to comply with lifestyle modification during the study period.\n* Clinically stable at the time of inclusion\n* The ability to understand the trial and completing it, as evaluated by the investigators.\n* Patients who may get pregnant should ensure using contraceptives for 20 months after inclusion Exclusion Criteria\n* History of malignancy in past 5 years\n* History of hypothyroidism, nephrotic syndrome, Cushing's syndrome or AIDS\n* History of chronic pancreatitis or pancreatic neoplasm\n* History of severe cardiovascular and pulmonary diseases, such as heart failure, coronary heart disease and chronic obstructive pulmonary disease.\n* Severe renal deficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin)\n* Severe hepatic deficiency (Child-Pugh Class B or C)\n* Previous pancreatic surgery\n* Recurrent AP due to pancreatic diverticulum\n* Recurrent AP due to known genetic mutations (eg. CFTR)\n* Personal or family history of medullary thyroid carcinoma (MTC)\n* Current or prior diagnosis or suspected diagnosis of multiple endocrine neoplasia type 2 (MEN2)\n* Serious hypersensitivity reaction to semaglutide or any of the excipients in the investigational drug or placebo\n* Pregnancy\n* Breast-feeding",{"count":96,"type":20},396,[98],"PHASE4","Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is associated with a high risk of recurrence despite standard lipid-lowering therapy and lifestyle modification. The goal of this clinical trial is to evaluate whether GLP-1 receptor agonist therapy can reduce the recurrence of HTG-AP in adults with a history of HTG-AP and hypertriglyceridemia.\n\nThe main questions this study aims to answer are:\n\n* Whether GLP-1 receptor agonist therapy reduces the recurrence rate of HTG-AP.\n* Whether GLP-1 receptor agonist therapy improves triglyceride control, body weight, and metabolic parameters.\n* Whether GLP-1 receptor agonist therapy is safe and well tolerated in this patient population.\n\nResearchers will compare GLP-1 receptor agonist therapy plus standard care with standard care alone to determine whether GLP-1 receptor agonist therapy provides additional benefit in preventing recurrent HTG-AP.\n\nParticipants will:\n\n* Receive either GLP-1 receptor agonist therapy plus standard care or standard care alone.\n* Undergo regular clinical follow-up visits and laboratory assessments.\n* Receive monitoring of triglyceride levels, recurrence events, metabolic outcomes, and adverse events during the study period.",[101,102,103,26],"Hypertriglyceridemia Induced Acute Pancreatitis","Recurrent Acute Pancreatitis","Pancreatitis Relapsing",[105,106,107,108,109],"hypertriglyceridemia-induced acute pancreatitis","recurrent acute pancreatitis","semaglutide","GLP-1 receptor agonist","pancreatitis prevention","NOT_YET_RECRUITING","2026-05-28",{"date":113,"type":32},"2026-06-01",{"date":115,"type":20},"2026-09",{"date":117,"type":20},"2028-12",{"name":119,"class":120},"Peking Union Medical College Hospital","OTHER",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":133,"conditions":134,"keywords":144,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100630707","phase-1-a-safety-and-tolerability-trial-evaluating-ctx310-in-participants-with-refractory-dyslipidemias-100630707","NCT07491172","A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias","A Phase 1 Open-label, Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety and Tolerability of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX310) for In Vivo Editing of the Angiopoietin-like 3 (ANGPTL3) Gene in Participants With Refractory Dyslipidemias","Key Inclusion Criteria:\n\n1. Age of ≥18 and ≤75 years at the time of signing the informed consent.\n2. Able to provide written informed consent.\n3. Participants diagnosed with persistent dyslipidemias defined by TG ≥150 mg\u002FdL - and LDL-C ≥70 mg\u002FdL in participants with ASCVD, or LDL-C ≥70 or 100mg\u002FdL in participants with or without ASCVD respectively, or TG ≥500 mg\u002FdL.\n4. Refractory to the maximal intensity or MTD of standard of care lines of lipid-lowering therapies available through routine clinical care, for at least 12 weeks prior to screening\n5. Female participants must be postmenopausal or surgically sterile.\n6. All male participants and their female partners must agree to the use of an acceptable method of effective contraception for the duration of the study.\n\nExclusion Criteria:\n\n1. Participants with familial chylomicronemia syndrome (FCS). Some exceptions may apply.\n2. Evidence of liver disease, defined as but not limited to:\n\n   LFTS \\>2 × upper limit of normal (ULN), or total bilirubin \\>2 × ULN, or INR \\>1.5 × ULN, or liver stiffness measured by liver elastography\n3. Abnormal or compromised function of kidney, heart, blood or liver.\n4. Acute coronary syndrome event or stroke within 24 weeks prior to Day 1. Acute pancreatitis within 12 weeks prior to Day 1.\n5. Current use or use within 365 days from Day 1 of any hepatocyte-targeted small interfering RNA (except inclisiran).\n6. Positive serology for HIV, hepatitis B or hepatitis C (antibody, surface antigen orNAT). Serology consistent with prior immunization will be eligible for the trial.\n7. Any prior malignancy within the past 5 years, or current malignancy (exceptions for resected or removed basal cell carcinoma, squamous cell carcinoma in situ and carcinoma in situ of the cervix or breast).\n8. Women of childbearing potential.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.\n\nNote: The inclusion and exclusion criteria listed represent the global protocol. Additional or modified eligibility criteria may apply in certain countries in accordance with local regulatory and ethics committee requirements and the approved country-specific protocol.","75 Years",{"count":130,"type":20},90,[132],"PHASE1","This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.",[135,136,137,138,26,139,140,141,142,143],"Cardiovascular","Metabolic Disease","Dyslipidemias","Lipid Disorder","Heterozygous Familial Hypercholesterolemia (HeFH)","Homozygous Familial Hypercholesterolemia (HoFH)","Severe Hypertriglyceridemia (sHTG)","Mixed Hyperlipemia","Hypercholesterolaemia",[145],"Refractory Dyslipidemias","2026-05-19",{"date":148,"type":32},"2026-05-22",{"date":150,"type":32},"2024-06-21",{"date":152,"type":20},"2028-06",{"name":154,"class":39},"CRISPR Therapeutics AG",18,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":177},"100640484","phase-2-rbd5044-in-chinese-participants-with-hypertriglyceridemia-100640484","NCT07587788","RBD5044 in Chinese Participants With Hypertriglyceridemia","A Multi-center, Randomized, Double-Blind, Placebo-Controlled Phase II Trial Evaluating the Efficacy and Safety of RBD5044 in Chinese Participants With Hypertriglyceridemia","Inclusion Criteria:\n\n1. The participants consented to participate in the clinical study and signed the informed consent form.\n2. Male or nonpregnant (who do not plan to become pregnant) nonlactating female participants aged 18 to 80 years inclusive.\n3. Established diagnosis of HTG and prior documented evidence (medical history) of fasting TG level ≥150 mg\u002FdL (≥1.7 mmol\u002FL) and \\\u003C500 mg\u002FdL (\\\u003C5.7 mmol\u002FL)\n4. Mean fasting TG level ≥150 mg\u002FdL (≥1.7 mmol\u002FL) and \\\u003C500 mg\u002FdL (\\\u003C5.7 mmol\u002FL) collected at 2 separate and consecutive visits at least 7 days apart and no more than 17 days apart during the screening period.\n5. Fasting LDL-C ≤130mg\u002FdL (≤3.4 mmol\u002FL) at screening\n6. Participants should be on standard of care lipid lowering medications per local guidelines (unless documented as intolerant or inappropriate as determined by the Investigator, including an inability to safely administer or re-administer a specific drug because of fear, preference, genetic, clinical, or metabolic considerations, or due to a previous adverse reaction associated with, attributed to, or caused by specific drug) prior to collection of qualifying TG levels. If TG-lowering medication is used (including fibrates and prescription omega-3 fatty acids) then use and dosage must be stable since≥6 weeks prior to screening.\n7. Participants using any of SOC treatment (such as anti-diabetes, anti-hypertension, Thyroid hormone replacement therapy, TG-lowering therapies, PCSK9 inhibitors treatment, retinoids etc.) must be on a stable regimen for the specified duration prior and for the duration of study participation.\n8. Female participants of childbearing potential must also be willing to practice abstinence from heterosexual intercourse (only if this reflects their preferred and consistent lifestyle) or be willing to use a highly effective method of contraception (i.e., with a failure rate of \\\u003C1%\u002Fyear) to prevent pregnancy from at least 2 weeks prior to the first administration of investigational medicinal product (IMP) to 90 days after study completion.\n\nExclusion Criteria:\n\n1. Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical trial and\u002For put the participant at significant risk (according to the investigator's judgment). This may include, but is not limited to, for example, known diagnosis of Familial Chylomicronemia Syndrome (FCS), nephrotic syndrome, thyroid disease, uncontrolled hypertension, psychiatric disorder or unstable angina.\n2. Body mass index \\>40 kg\u002Fm2\n3. Uncontrolled hypertension (blood pressure \\>160\u002F100 mmHg at screening). If untreated, participant may be re-screened once hypertension is treated and controlled.\n4. Active or history of serious mental illness or psychiatric disorder, including but not limited to schizophrenia, bipolar disorder, or severe depression, which require current pharmacological intervention. Participants with a history of severe depression who are no longer on medication.\n5. Any of the following laboratory values at screening:\n\n   * Hepatic: ALT or AST \\>2× ULN at screening,\n   * Biliary obstruction or hyperbilirubinemia (ie, total bilirubin \\>2 × ULN, except with a documented diagnosis of Gilbert's disease) at screening,\n   * eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2 (using the Modification of Diet in Renal Disease \\[MDRD\\] equation) at Screening,\n6. -HbA1c \\>9.0% (or \\>75 mmol\u002Fmol International Federation of Clinical Chemistry \\[IFCC\\] units) at screening. The participant will be excluded if they have diabetes and meet any of the following criteria:\n\n   * Two HbA1c readings (≥4 weeks apart) during the screening period, with at least one reading \\>9.0%. (If a participant is screen-failed based on HbA1c criteria, the investigator may optimize the anti-diabetic regimen and re-screen the participant.)\n   * Any history of the following within 12 weeks prior to the screening period: diabetic ketoacidosis, diabetic decompensation\u002Fhyperosmolar hyperglycemic state, diabetes complications, recurrent infections, or hospitalization due to poor glycemic control.\n   * For participants with insulin-dependent diabetes: Any change in basal insulin of more than ±10 units during the 12 weeks prior to Day 1, indicating an unstable insulin regimen.\n7. Received any siRNA for lipids\u002FTGs (other than inclisiran) within 365 days before Day 1. Administration of investigational drug and inclisiran must be separated by at least 4 weeks.\n8. Any other siRNA or antisense oligonucleotide within 60 days or 5 target engagement half-lives (whichever is longer), or any other investigational product within 30 days or 5 target engagement half-lives (whichever is longer) before the first dose, with the exception that inclisiran is permitted if administered at least 4 weeks apart from the trial drug.\n9. Participants who were positive for hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb), hepatitis C virus antibody (HCVAb), or human immunodeficiency virus antibody (HIVAb) at screening.\n10. Clinically significant illness within 7 days before the first dose of the trial drug. A clinically significant illness is defined as one that is new or acutely worsened, requires intervention, may interfere with study assessments, or significantly increases the participant's risk.\n11. Acute pancreatitis within 3 months prior to first investigational product administration.\n12. Participants with a history of symptomatic gallbladder disease prior to the first dose (e.g., cholecystitis, choledocholithiasis, multiple gallstones, etc, unless cholecystectomy was performed at least 6 months prior).\n13. History of malignancy within the past 5 years (with the exception of cured basal cell carcinoma, localized squamous cell carcinoma of the skin, or carcinoma in situ of the cervix), or currently under evaluation for a potential malignancy.\n14. Any planned bariatric surgery or similar procedures to induce weight loss during the period starting at consent through EOS.\n15. History of major surgery within 12 weeks or planned major surgery during the study\n16. Planned coronary intervention (such as stent placement or heart bypass) during the study.\n17. Acute or unstable myocardial ischemia (myocardial infarction, acute coronary syndrome, new angina pectoris, stroke, transient ischemic attack, or unstable congestive heart failure) within 6 months prior to screening or major cardiovascular surgery planned within 3 months after screening.\n18. . Recent unstable or symptomatic cardiac arrhythmia requiring hospitalization (including any associated medication changes) within 90 days of the beginning of screening.\n19. Alcohol abuse (men drinking more than 14 standard units per week, women drinking more than 9 standard units per week) within 3 months prior to screening. 1 standard unit containing 14g of alcohol, such as 360mL of beer or 45mL of spirits with 40% alcohol or 150mL of wine), or a positive alcohol B-PEth test, at the discretion of the investigator, is not suitable for participation in the study.\n20. History or clinical evidence of drug abuse within the 12 months before screening. Drug abuse is defined as compulsive, repetitive, and\u002For chronic use of drugs or other substances with or without problems related to their use and\u002For where stopping or a dose reduction will lead to withdrawal symptoms.\n21. Donated more than 500 mL of blood within 56 days before the first dose of the trial drug.\n22. Participants with severe allergies (multiple drug and food allergies), or allergies to GalNAc and antisense oligonucleotides (ASO) components are determined by the investigator to be unsuitable for participation in this study.\n23. History of severe intolerance to subcutaneous (SC) injection (minor reactions are permitted, e.g. localized swelling or redness.).\n24. Any conditions which would make the participant unsuitable for enrollment or could interfere with the participant's participation in or completion of the trial in the opinion of the investigator.\n25. Unwillingness to comply with lifestyle and diet management requirements.\n26. Pregnant or breastfeeding participants or participants intending to become pregnant during the trial and within 90 days after study completion.","80 Years",{"count":165,"type":20},40,[23],"The goal of this clinical trial is to learn if drug RBD5044 works to treat hypertriglyceridemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are:\n\nDoes drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat hypertriglyceridemia.\n\nParticipants will:\n\nReceive RBD5044 or placebo twice during the trial (Day 1 and Day 84).",[26],{"date":170,"type":32},"2026-05-14",{"date":172,"type":32},"2026-02-28",{"date":174,"type":20},"2027-03",{"name":176,"class":39},"Ribotek Biopharmaceuticals (Shandong) Co., Ltd",8,{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":21,"phases":188,"briefSummary":189,"conditions":190,"keywords":193,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100550799","phase-1-phase-1b-study-of-verve-201-in-patients-with-refractory-hyperlipidemia-100550799","NCT06451770","Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia","A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia","Inclusion Criteria:\n\n* Refractory hypercholesterolemia\n* Refractory hypertriglyceridemia\n\nExclusion Criteria:\n\n* Active or history of chronic liver disease\n* Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe\n* Clinically significant or abnormal laboratory values as defined by the protocol","70 Years",{"count":187,"type":20},36,[132],"VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.\n\nVERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.",[191,26,192],"Hypercholesterolemia","Refractory Hyperlipidemia",[194,195,196,197,198,199,200,192,201],"VERVE-201","Gene Editing","Base Editing","Refractory Hypercholesterolemia","ANGPTL3","ASCVD","Refractory Hypertriglyceridemia","Familial Hypercholesterolemia","2026-04-22",{"date":204,"type":32},"2026-04-28",{"date":206,"type":32},"2024-10-30",{"date":208,"type":20},"2027-12",{"name":210,"class":39},"Verve Therapeutics, Inc.",10,{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":220,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":21,"phases":223,"briefSummary":225,"conditions":226,"keywords":227,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":63},"100593310","effect-of-consuming-n-3-polyunsaturated-fatty-acids-rich-foods-on-triglyceride-concentration-and-lipoprotein-composition-100593310","NCT07004777","Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition","Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition in Individuals With Hypertriglyceridemia. Controlled Clinical Trial.","SALVIMEX","Inclusion Criteria:\n\n* Signing of the informed consent form\n* Both sexes.\n* Adults over 18 years of age.\n* BMI \\>18.5 kg\u002Fm2.\n* Triglycerides between 200 and 500 mg\u002FdL.\n* Total cholesterol less than 240 mg\u002FdL\n\nExclusion Criteria:\n\n* Any type of diabetes.\n* kidney disease diagnosed by a physician.\n* Acquired diseases that secondarily cause obesity and diabetes.\n* Patients who have suffered a cardiovascular event.\n* Weight loss \\>3 kg in the last 3 months.\n* Catabolic diseases such as cancer and acquired immunodeficiency syndrome.\n* Pregnancy.\n* Treatment with any medication:\n* Treatment with antihypertensive drugs (tricyclic, loop, or potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, alpha-blockers, calcium channel blockers, beta-blockers).\n* Treatment with hypoglycemic agents (sulfonylureas, biguanides, incretins) or - insulin and antidiabetics.\n* Treatment with statins, fibrates, or other drugs to control dyslipidemia.\n* Use of steroid medications, chemotherapy, immunosuppressants, or radiation therapy.\n* Anorectic agents or those that accelerate weight loss.\n* Treatment with any medication that influences inflammation (corticosteroids, nonsteroidal anti-inflammatory drugs, colchicine, interleukin-1 inhibitors) or triglyceride metabolism (metformin, glitazones, SGLT2 inhibitors, fibrates, statins, cholesterol ester transporter protein (CETP) inhibitors, pancreatic lipase inhibitors).\n* Anticoagulants and antiplatelets (warfarin, aspirin, clopidogrel).\n* People with a smoking cessation index (SCI) greater than 21.\n* People with a tobacco Index greater than 21.\n* Consumption of large amounts of alcohol (14 drinks for women or 21 drinks for men in a typical week).\n* Consumption of any recreational psychoactive substance.\n* Allergy or intolerance to any food listed in the proposed pantry.\n* Unwillingness to consume any of the foods listed in the proposed pantry.\n* Previous n-3 PUFA supplementation.",true,{"count":222,"type":20},375,[224],"NA","Hypertriglyceridemia is one of the most prevalent lipid profile disorders and is linked to a large proportion of mortality in Mexico and around the world. Various international treatment guidelines for hypertriglyceridemia have suggested the consumption of foods rich in n-3 polyunsaturated fatty acids or their intake through supplementation as a complement to lifestyle changes. However, adherence to the consumption of foods and supplements containing these fatty acids is often limited due to lack of acceptance or unaffordability. For this reason the objective of the study is to evaluate the effect of including Mexican foods rich in n-3 polyunsaturated fatty acids (chia seeds and pumpkin seeds) within a diet based on NCEP-ATPIII recommendations on triacylglycerol concentration and fatty acid profile in people with hypertriglyceridemia.\n\nThe study will consist of a 4-week period in which one group of participants will be randomized into two treatment groups: 1)isocaloric diet based on the NCEP-ATPIII dietary recommendations; 2) isocaloric diet based on the NCEP-ATPIII dietary recommendations plus chia and pumpkin seeds. The effect of the dietary intervention will be assessed by concentration of triglycerides, fatty acids profile and lipoprotein analysis.",[26],[26,228,229,230,231,232,233],"Lipid metabolism","Dyslipidemia","Fatty Acids, Omega-3","Eicosapentaenoic Acid","Docosahexaenoic Acid","diet","2026-04-09",{"date":236,"type":32},"2026-04-14",{"date":238,"type":32},"2026-02-01",{"date":240,"type":20},"2027-06-30",{"name":242,"class":120},"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":251,"targetDuration":253,"studyType":254,"phases":4,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":269},"100632072","russian-extreme-hypertriglyceridemia-registry-100632072","NCT07508930","Russian Extreme Hypertriglyceridemia Registry","Russian Extreme Hypertriglyceridemia Registry (REGGI)","REGGI","Inclusion Criteria:\n\n* Patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol\u002FL), confirmed by at least two independent measurements.\n* Written informed consent from the patient or legal guardian.\n* No age restrictions.\n\nExclusion Criteria:\n\n* Patients whose extreme hypertriglyceridemia is caused by alcohol abuse, uncontrolled diabetes, or other medical conditions, unless extreme hypertriglyceridemia is confirmed after controlling the underlying condition.\n* Lack of informed consent.",{"count":252,"type":20},500,"20 Years","OBSERVATIONAL","The REGGI registry is a prospective, multicenter observational registry in Russia designed to collect data on patients with extreme hypertriglyceridemia (triglyceride levels ≥10 mmol\u002FL). The registry aims to describe the clinical, demographic, and molecular-genetic characteristics of patients, as well as current diagnostic approaches and treatment patterns in real-world practice. The collected data may inform future research and support improvements in patient care.",[26],[258,259],"Acute Pancreatitis","cardiovascular diseases","2026-03-27",{"date":262,"type":32},"2026-04-02",{"date":264,"type":32},"2025-11-20",{"date":266,"type":20},"2045-12",{"name":268,"class":120},"Russian Cardiology Research and Production Center",6,{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":21,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":63},"100496410","metabolic-heterogeneity-underlying-hypertriglyceridemia-hepatic-triglyceride-biosynthesis-in-humans-with-different-insulin-resistance-phenotypes-100496410","NCT05743868","Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans With Different Insulin Resistance Phenotypes","Inclusion Criteria:\n\n* Ability to give informed consent\n* Overweight, defined as BMI 25-30 kg\u002Fm2\n* Modest hypertriglyceridemia, defined as fasting plasma triglycerides 1.5-3.0mM\n* High risk of insulin resistance, defined as fasting plasma insulin \\>64pM\n* Stable weight for at least 3mo prior to participation\n\nExclusion Criteria:\n\n* Active or chronic liver disease, kidney disease, congestive heart failure, unstable angina, history of acute cardiovascular events within 6mo of screening, history of seizures or syncope, or an active infection requiring antimicrobial therapy;\n* Use of insulin, thiazolidinediones, SGLT2 inhibitors, or sulfonylureas;\n* Use of fibrates, omega 3 (fish oil), niacin, or PCSK9 antagonists;\n* Use of systemic glucocorticoids within 60d prior to participation;\n* Hematocrit \\\u003C35%;\n* Pregnancy of breastfeeding;\n* Active tobacco use, excessive alcohol intake (\\>14U\u002Fwk), or history of drug abuse.","65 Years",{"count":165,"type":20},[224],"The focus of this cross-sectional study is to determine the effects of tissue-specific (adipose tissue or muscle) vs global (combined) insulin resistance (IR) on hepatic triglyceride biosynthesis in humans, and to determine differential effects of an acute exercise intervention on hepatic triglyceride biosynthesis in these groups.",[281,26],"Insulin Resistance","2026-01-23",{"date":284,"type":32},"2026-01-27",{"date":286,"type":32},"2023-11-16",{"date":288,"type":20},"2026-06",{"name":290,"class":120},"Yale University",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":128,"enrollmentInfo":299,"targetDuration":4,"studyType":21,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":63},"100603768","phase-1-a-phase-1b2a-study-of-jmt202-injection-in-participants-with-hypertriglyceridemia-100603768","NCT07140809","a Phase 1b\u002F2a Study of JMT202 Injection in Participants With Hypertriglyceridemia","a Multiple-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Escalation Phase Ib\u002FⅡa Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetic Characteristics of JMT202 Injection in Chinese Participants With Hypertriglyceridemia","phase Ib\u002FⅡa st","Inclusion Criteria:\n\n* Age ≥18 and ≤75 years old (at the time of signing the informed consent form), gender not limited.\n* The weight is ≥45.0 kg (for females) or ≥50.0 kg (for males), and the body mass index is between 24.0 and 40.0 kg\u002Fm ² (including the cut-off value). The body mass index is calculated as \\[BMI= weight (kg)\u002Fheight 2 (m ²)\\].\n* TG\\>300 mg\u002FdL (3.39 mmol\u002FL) within 28 days before screening; During the screening period, the TG of the participants met the following requirements: ① Two TG values within the screening period, with an interval of ≥7 days, and both TG values met the requirement of 300 mg\u002FdL≤TG\\\u003C1000 mg\u002FdL (11.30 mmol\u002FL); ② The last TG test was less than 7 days before administration (D1).\n* Participants need to meet:\n\n  1. Receive stable lipid-lowering treatment for ≥28 days before screening;\n  2. Accept lipid-lowering medications before screening of less than 28 days, but random stable lipid-lowering therapy, 28 days or more before test TG and D - 1 \\> 300 mg\u002FdL (the tendency for 3.39 L) screening of unused lipid-lowering within 28 days before,\n  3. During the screening period, at least one screening should be conducted at a concentration of 300 mg\u002FdL (3.39 mmol\u002FL) ≤TG\\\u003C500 mg\u002FdL (5.65 mmol\u002FL).\n  4. Screening unused lipid-lowering, within 28 days before screening period two TG 500 mg\u002FdL or higher tendency (5.65 L), need before random stable lipid-lowering therapy, 28 days or TG test and D - 1 \\> 300 mg\u002FdL (the tendency for 3.39 L).Lipid-lowering treatment: niacin ≥375 mg\u002F day, prescription fish oil, fibrates, statins, ezetimibe, etc. PCSK9 inhibitors need to be stable for 6 months before screening.\n* Some participants (at least 4 cases per dose group) had MRI-PDFF≥8%;\n* From 28 days before screening to the entire trial period, participants should maintain their original diet, exercise and lifestyle habits as much as possible, and avoid alcohol and strenuous exercise within 48 hours before each visit.\n* Participants and their partners agree that they must use effective and reliable contraceptive methods from the signing of the informed consent form until 6 months after the end of the trial (female participants are not allowed to use hormonal contraceptives from 14 days before screening until the entire trial period) to prevent pregnancy in either female or male participants' partners. Male participants had no sperm donation plans from signing the informed consent form to 6 months after the end of the trial, and female participants had no egg donation plans from signing the informed consent form to 6 months after the end of the trial.\n* Participants voluntarily join the clinical trial and sign the informed consent form, and have the ability to communicate normally with the researchers while abiding by the trial requirements.\n\nExclusion Criteria:\n\n* Weight changed by ≥5% within the 3 months prior to randomization, or who planned to lose weight throughout the trial period;\n* Screening products targeting the FGF21 target that have been used within the previous year, such as BIO89-100, DR10624, etc.\n* Participants with Type 1 diabetes No stable hypoglycemic drug treatment within 3 months prior to screening or randomization (the use of glucagon-like peptide-1 receptor agonists, single-target or multi-target drugs, thiazolidinediones or insulin was prohibited from 3 months prior to screening until the entire trial period) Other oral or injectable drugs should have been stably treated for ≥3 months before screening and the dose should be maintained stably throughout the trial period, or the glycated hemoglobin should be ≥9.5% during the screening period.\n* Participants who are known or suspected of having familial hyperchylomicemia, lipoprotein lipase injury or deficiency (Fredrickson type 1), apolipoprotein C-II deficiency or familial lipoprotein dyslipidemia (Fredrickson type 3);\n* Participants with a history of gallbladder disease and have symptoms before Screen or randomly (such as common bile duct stones, multiple gallbladder stones, etc., unless the gallbladder has been removed and the removal time is ≥6 months);\n* Participants had a history of acute pancreatitis attacks or chronic pancreatitis within 12 months prior to screening or randomization;\n* Subjects with atherosclerotic cardiovascular diseases in the 6 months prior to screening or randomization, including acute coronary syndrome, stable coronary heart disease, post-revascularization, ischemic cardiomyopathy, ischemic stroke, transient ischemic attack, peripheral atherosclerotic disease, etc., or those diagnosed with a high risk of atherosclerotic cardiovascular disease;\n* There were major cardiovascular and cerebrovascular diseases in the 6 months prior to screening or randomization;\n* Having a history of malignant tumors in the past five years (excluding cured basal cell carcinoma of the skin, localized squamous cell carcinoma of the skin or carcinoma in situ of cervical cancer), or potential malignant tumors currently under assessment;\n* Participants have experienced severe infections within the three months prior to screening, including but not limited to: severe pneumonia, lung abscess, meningitis, cellulitis, etc., and are judged by the researchers as unsuitable to participate in this trial;\n* Participants with poor blood pressure control during the screening period (systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg); Or the antihypertensive drugs of the participants have not been stable for ≥3 months before screening or randomization (thiazide diuretics and beta-blockers are prohibited from 3 months before screening to the entire trial period).\n* Participants test positive for any one of hepatitis B surface antigen, hepatitis C virus antibody, Treponema pallidum antibody or human immunodeficiency virus antibody;\n* Other lipid regulators (excluding lipid-lowering drugs in inclusion criterion 4) were used from 28 days before screening\u002Frandomization to the entire trial period (≥3 days), including niacin (\\\u003C375 mg\u002F day), over-the-counter or non-pharmaceutical strength fish oil, red rice yeast supplements, garlic supplements, soy isoflavone supplements, sterols\u002Fsterol products, polyphenols, etc.\n* In the opinion of the investigator, the participants have symptoms such as dermatitis or abnormal skin around the abdominal administration site;\n* Participants with a history of severe drug or food allergies, who have used immunosuppressant drugs, or who are determined by the researcher to be allergic to the investigational drug;",{"count":300,"type":20},48,[132,23],"To evaluate the safety and tolerability of multiple subcutaneous injections of JMT202 injection in Chinese participants with hypertriglyceridemia",[26],"2025-12-22",{"date":306,"type":32},"2025-12-30",{"date":308,"type":32},"2025-09-09",{"date":310,"type":20},"2026-10-01",{"name":312,"class":39},"Shanghai JMT-Bio Inc.",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":128,"enrollmentInfo":320,"targetDuration":4,"studyType":21,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":63},"100608265","phase-2-a-mechanistic-study-of-mar001-in-adults-with-elevated-triglycerides-and-remnant-cholesterol-100608265","NCT07199309","A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol","Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of MAR001 on Postprandial Lipids in Patients With Elevated Triglycerides and Remnant Cholesterol","Inclusion Criteria:\n\n* Willingness to provide informed consent and comply with the intervention and all study assessments\n* Two fasting TG collected at two separate, consecutive visits at least 7 days apart during the Screening period\n* HbA1c ≥ 5.7% and ≤ 8.5%\n* Stable diet for a minimum of 3 months prior to screening and with no plans to change diet through duration of study\n* Stable drug regimen (appropriate if relevant) prior to screening visit and no planned changes during screening or trial participation\n\nExclusion Criteria:\n\n* Acute or chronic liver disease\n* Diabetes medications (other than metformin)\n* History of type 1 diabetes mellitus or history of diabetic ketoacidosis\n* Newly diagnosed T2DM\n* Participants with known active hepatitis A, B, or C\n* Participants who are known to have uncontrolled human immunodeficiency virus (HIV) infection\n* Uncontrolled hypothyroidism\n* Any condition that prevents the participant from complying with study procedures",{"count":321,"type":20},30,[23],"The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.",[26],[326,327,26],"Remnant Cholesterol","MAR001","2025-11-04",{"date":330,"type":32},"2025-11-06",{"date":332,"type":32},"2025-09-26",{"date":334,"type":20},"2026-11",{"name":336,"class":39},"Marea Therapeutics",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":21,"phases":347,"briefSummary":349,"conditions":350,"keywords":352,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":63},"100554084","early-phase-1-differential-thrombogenesis-by-epa-and-dha-mediated-by-hdl-100554084","NCT06494488","Differential Thrombogenesis by EPA and DHA Mediated by HDL","Differential Thrombogenesis Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Mediated by High-Density Lipoprotein (HDL)","Inclusion Criteria:\n\n* Fasting TG levels ≥ 150 mg\u002FdL and \\\u003C 500 mg\u002FdL and HDL-C ≤ 40 (men) or ≤ 50 (women)\n* LDL-C \\> 40 mg\u002FdL and ≤ 130 mg\u002FdL\n* Able to provide informed consent and adhere to study schedules\n* Agree to follow and maintain a relatively stable and low fatty fish intake diet (\\\u003C3 servings per week)\n\nExclusion Criteria:\n\n* Female with pregnancy, planned pregnancy (within the study period), or currently breastfeeding.\n* Subjects with weight changes greater than 20% over the past 3 months\n* Subjects planning a significant change in diet or exercise levels\n* Malabsorption syndrome and\u002For chronic diarrhea\n* Use of dietary supplements containing n-3 PUFA fatty acids\n* Frequent consumption of n-3 PUFA-enriched fish (\\>3 times a week)\n* Abnormal liver, kidney, or thyroid functions\n* Drug or alcohol abuse within 6 months or significant mental\u002Fpsychological impairment\n* Current smokers\n* Subjects taking daily aspirin, NSAIDs, anticoagulant, or corticosteroids\n* Subjects with known bleeding disorders (for example, hemophilia)\n* Known sensitivity or allergy to fish, shellfish, or omega-3 fatty acid supplements\n* Subjects requiring regular transfusions for any reason\n* No ethnic\u002Fracial groups will be excluded","69 Years",{"count":346,"type":20},80,[348],"EARLY_PHASE1","The goal of this study is to learn more about omega-3 polyunsaturated fatty acids supplementation on blood lipid profile and platelets in patients with high cholesterol levels.\n\nThe purpose of this research is to gather information on the safety and effect of two different fish oils, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\n\nParticipants will:\n\nVisit the clinic 3 times during study checkups, tests and blood collection. Randomized to either the EPA or the DHA supplementation group. Be given a 28-day food and activity log.",[351,26],"Lipid Metabolism Disorders",[353,354,355],"Fish oil","Atherogenic lipidemia","Lipoproteins","2025-09-25",{"date":358,"type":32},"2025-10-01",{"date":360,"type":32},"2025-07-10",{"date":362,"type":20},"2028-03-31",{"name":364,"class":120},"The Miriam Hospital",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":374,"conditions":375,"keywords":376,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":63},"100608370","interest-of-high-speed-centrifugation-for-measuring-anti-xa-activity-on-lipemic-plasma-100608370","NCT07200674","Interest of High-speed Centrifugation for Measuring Anti-Xa Activity on Lipemic Plasma","LCGV","Inclusion Criteria:\n\n* Adult patient (≥ 18 years)\n* Patient anticoagulated with an anti-Xa (UFH, LMWH, fondaparinux, danaparoid, apixaban, rivaroxaban)\n* Sample sent to the HUS Hematology Laboratory and analyzed for measurement of the anti-Xa activity of an anticoagulant as part of routine care\n\nExclusion Criteria:\n\n* Patient with a basal lipidemic sample\n* Sample of insufficient volume",{"count":373,"type":20},150,"Some hemostasis techniques require spectrophotometric measurements. These are then subject to interference from the sample's lipemia (postprandial, hypertriglyceridemia, etc.), which risks distorting the results; this is estimated to affect 0.5 to 2.5% of samples.\n\nThis is particularly the case for anti-Xa activity, a critical test used to monitor anticoagulant treatments.\n\nTo date, the HUS Hematology Laboratory does not have or is aware of any alternative method to overcome this interference, and is unable to perform anti-Xa activity when the sample has excessive lipemia. This study will evaluate, on samples from routine care artificially overloaded with lipids, the effectiveness of a high-speed centrifugation process (10,800g for 10 minutes).",[26],[26,377,378,379,380,381],"High-Speed Centrifugation","Anti-Xa Activity","Lipemic Plasma","Hemostasis","Hematology","2025-09-22",{"date":358,"type":32},{"date":385,"type":32},"2024-03-11",{"date":387,"type":20},"2025-12-11",{"name":389,"class":120},"University Hospital, Strasbourg, France",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":397,"enrollmentInfo":398,"targetDuration":4,"studyType":254,"phases":4,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":63},"100531973","vitamin-c-administration-and-triglycerides-level-in-critical-care-patients-100531973","NCT06206759","Vitamin C Administration and Triglycerides Level in Critical Care Patients","Vitamin C Administration and Triglycerides Level in Critical Care Patients: a Retrospective Study","Inclusion Criteria: patients aged 18-99 who were admitted to the general intensive care unit from January 2017 to December 2023, and who were treated with intravenous vitamin C. The control group will include patients with the same characteristics who were not treated with vitamin C.\n\nExclusion criteria: patients who did not meet the above conditions or for whom data were missing.\n\n\\-\n\n\\-","99 Years",{"count":399,"type":20},2000,"Vitamin C (ascorbic acid) is a water-soluble vitamin with antioxidant properties. Previous studies showed that the administration of vitamin C was associated with decreased triglyceride (TG) levels in ambulatory patients, especially in patients with type 2 diabetes. The decrease in TG level was more significant the younger the patient's age (less than 52.8 years), the longer the administration of vitamin C lasted (over 12 weeks) and the higher the daily dose was (over 1 gram per day) (2). However, we did not find any studies that examined the relationship between administration of vitamin C and lowering of TG level in critical patients in intensive care. High TG levels are often found in these patients, secondary to sepsis, administration of propofol by continuous infusion, administration of TPN, pancreatitis, liver failure and chronic dyslipidemia, diabetes and chronic renal failure. High TG levels in these patients may cause pancreatitis secondary to elevated TG, and we take several actions to lower TG levels in the unit when they exceed 500 mg per dL in order to avoid these complications. The actions taken include starting treatment with fibrates and\u002For statins, giving high-dose insulin, stopping the propofol drip and changing it to another hypnotic drug (usually midazolam), and giving fat-free TPN instead of fat-containing TPN. There are of course disadvantages to these interventions, such as drug interactions, longer clearance time and higher incidence of delirium when giving midazolam compared to propofol, hypoglycemia when giving a continuous insulin drip in high doses and giving a lower amount of calories to a patient who will receive TPN without lipids.\n\nThere are many studies that examined the administration of vitamin C to patients in intensive care, especially patients with sepsis, with varied but inconclusive results. A recently published meta-analysis found a reduction in mortality among critical intensive care patients treated with intravenous vitamin C, especially in the subgroup of critically ill patients with a high risk of in-hospital mortality. The drug was found to be safe for use among patients in intensive care. In these patients in the various studies, vitamin C treatment was given intravenously in different doses, with most patients receiving a dose of 6 grams per day for 3-5 days. In light of a trend about five years ago that showed an improvement in survival among septic patients in intensive care who were treated with intravenous vitamin C as monotherapy, or in combination with steroids and\u002For intravenous thiamine, also in the intensive care unit at our institution (as well as in other hospitals) we started giving this treatment, at the recommended dose of 6 grams per day for 3-5 days. Over time, new studies did not find clear benefits for this treatment, so we gradually stopped giving it. However, if indeed vitamin C can contribute to a significant decrease in TG levels in patients in intensive care, there may be a point in administering it to a group of patients with high TG levels, in order to reduce complications associated with a high TG level and\u002For treatment to reduce it.",[26],"2025-05-07",{"date":404,"type":32},"2025-05-11",{"date":406,"type":32},"2024-05-01",{"date":408,"type":20},"2027-02-01",{"name":410,"class":120},"Meir Medical Center",{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":185,"enrollmentInfo":418,"targetDuration":4,"studyType":21,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":432},"100559473","phase-2-phase-2a-study-of-safety-tolerability-and-efficacy-of-tlc-2716-in-subjects-with-hypertriglyceridemia-and-nafld-100559473","NCT06564584","Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD","A Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and Nonalcoholic Fatty Liver Disease","Inclusion Criteria:\n\n* BMI ≥ 28 kg\u002Fm2 at Screening\n* Fasting TG ≥ 350 mg\u002FdL\n* Subjects without diabetes or subjects with diabetes and HbA1c \\\u003C 9.5% at Screening\n* Screening laboratory evaluations (eGFR, ALT, AST, INR, total bilirubin, platelet count) must fall within the protocol-defined ranges\n* A clinical diagnosis of NAFLD\u002FNASH within 5 years of Screening based on historical hepatic imaging (e.g., ultrasound, MRI, computed tomography \\[CT\\], or Controlled Attenuation Parameter \\[CAP\\] by vibration-controlled transient elastography ≥ 250 dB\u002Fm), and no documented weight loss \\> 5% between the date of the historical hepatic imaging and Screening OR a historical liver biopsy within 5 years of Screening consistent with NAFLD\u002FNASH without cirrhosis and no documented weight loss \\> 5% between the date of the historical liver biopsy and Screening\n* Normotensive subjects or subjects without uncontrolled hypertension, defined as systolic blood pressure \\> 155 mmHg and\u002For diastolic blood pressure \\> 90 mmHg at Screening\n* A 12-lead electrocardiogram (ECG) at Screening that is normal or with abnormalities that are considered not clinically significant by the investigator\n* Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 prior to first dose of study drug\n* Male and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception\n\nExclusion Criteria:\n\n* HbA1c ≥ 9.5% at Screening\n* Weight loss \\> 5% during the 90 days prior to Screening\n* Pregnant or lactating subjects.\n* Current alcohol abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety\n* Current substance abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety\n* A positive test result for human immunodeficiency virus (HIV-1) antibody, hepatitis B (HBV) surface antigen, or hepatitis C (HCV) antibody\n* Medical history of liver disease other than NAFLD\u002FNASH, including but not limited to, alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1-antitrypsin deficiency.\n* Any history of cirrhosis or decompensated liver disease, including ascites, hepatic encephalopathy, or variceal bleeding, or Child-Pugh-Turcotte score \\> 6 at Screening\n* Unstable cardiovascular disease\n* History of intestinal resection or malabsorptive condition that may limit the absorption of study drug. Appendectomy and cholecystectomy are not exclusionary.\n* Presence of severe peptic ulcer, gastroesophageal reflux disease, or other gastric acid hypersecretory conditions at Screening, in the opinion of the investigator\n* Any scheduled surgery during the trial period, excluding minor surgical procedures performed under local anesthesia, in the opinion of the investigator\n* History of malignancy within 5 years prior to Screening except adequately treated carcinoma in situ of the cervix, and\u002For squamous cell cancer, or other localized non-melanoma skin cancer\n* History of significant drug allergy, such as anaphylaxis or significant drug sensitivity, in the opinion of the investigator\n* Known hypersensitivity to study drug, its metabolites, or formulation excipients\n* Presence of any medical condition that could, in the opinion of the investigator, compromise the subject's ability to participate in the study, including a history of substance abuse or a psychiatric disorder, including any subject with a psychiatric hospital admission or emergency room visit in the 2 years prior to Screening\n* Any laboratory abnormality that in the opinion of the investigator could adversely affect the safety of the subject or impair assessment of study results\n* Medications or therapies prescribed or taken over-the-counter for weight loss, in the 90 days prior to Screening\n* Receipt of vaccination for COVID-19 or any other live vaccine within 14 days of planned dosing of study drug\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply",{"count":321,"type":20},[23],"This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.",[26,422],"Nonalcoholic Fatty Liver Disease","2025-03-31",{"date":425,"type":32},"2025-04-03",{"date":427,"type":32},"2024-08-12",{"date":429,"type":20},"2025-09",{"name":431,"class":39},"OrsoBio, Inc",4,{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":220,"sex":16,"minAge":17,"maxAge":441,"enrollmentInfo":442,"targetDuration":4,"studyType":21,"phases":443,"briefSummary":444,"conditions":445,"keywords":451,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":63},"100558748","exploring-physical-exercise-for-the-regulation-and-control-of-metabolic-disorders-in-college-students-100558748","NCT06555159","Exploring Physical Exercise for the Regulation and Control of Metabolic Disorders in College Students.","EFFECT OF AN AEROBIC EXERCISE PROGRAM ON METABOLIC DISORDERS LEVELS IN HIGHER EDUCATION STUDENTS AT THE UNIVERSITY OF COLIMA, RANDOMIZED CLINICAL TRIAL.","(EPE_RCTMCS)","Inclusion Criteria:\n\n* University of Colima students linked to the central campus.\n* Students aged between 18 and 25 years old.\n* Authorization to participate in the project with a signed informed consent.\n* Suffer from at least one of the parameters of metabolic disorders or cardiovascular risk (Hyperglycemia, decreased DHL, elevated triglycerides, abdominal obesity or hypertension) following the clinical assessment (Considering the criteria established by the ADA and ATPIII).\n\nExclusion Criteria:\n\n* Motor limitations that may hinder the performance of physical exercise.\n* Pregnancy or lactation.\n* High Vigorous Physical Activity Level according to the IPA-Q.\n* To be currently under pharmacological treatment to manage altered metabolic levels.\n\nELIMINATION CRITERIA\n\n* Musculoskeletal injuries during the study period.\n* Unforeseen Medical Events: Unexpected medical situations that could influence study results, such as hospitalizations, serious illnesses, or surgeries.\n* Non-Compliance with Follow-Up: Subjects failing to meet a minimum of 80% (19 out of 24 sessions) of the stipulated physical conditioning program time.\n* Initiation of clinical treatment that may affect protocol results, such as medications that reduce alterations.\n* Participants who voluntarily withdraw from the study.","25 Years",{"count":300,"type":20},[224],"This clinical trial objective is to evaluate the effect of an aerobic physical exercise program on reducing triglycerides, blood pressure, abdominal obesity, altered glucose levels, and the increase in HDL in college-level students at the University of Colima. It will try to answer whether aerobic physical exercise reduces metabolic disorders (altered blood pressure and glucose levels, abdominal obesity, and increased HDL). A simple randomized clinical trial will be conducted with a sample of 48 voluntary students from the University of Colima, divided into two groups of 24 people (Control group -A-, will perform aerobic physical exercise, which will be walking at 57% to 76% of HRmax; and Experimental Group -B-, will undergo an aerobic physical exercise (APE) program involving jogging, swimming, and static cycling, with a progressive intensity, which will start at 57%-63% of the maximum heart rate (HRmax) in the first 4 weeks of the study, and will increase to 64% -76% in the final four weeks, fulfilling the principle of progressive overload).\n\nResearchers will compare the results of both groups to confirm the effectiveness of the planned aerobic physical exercise in reducing these risks.",[446,447,448,26,449,450],"Metabolic Disorders","Abdominal Obesity","Blood Pressure Disorders","Hyperglycemia","HDL-Deficiency",[452,453,454,455,456],"Exercise","Obesity","HDL","Triglycerides","Hypertension",{"date":458,"type":32},"2024-08-15",{"date":460,"type":20},"2024-09",{"date":462,"type":20},"2025-06",{"name":464,"class":120},"Universidad de Colima"]